Brief Definitive Report

Extrahepatic Transcription of Human C-reactive Protein

By Therese M. Murphy, Linda L. Baum, and Kenneth D. Beaman

From the Department of Microbiology and Immunology, The University of Health Sciences/The Chicago Medical School, North Chicago, Illinois 60064

Summary
We synthesized and cloned cDNA from human peripheral blood mononuclear cell (PBMC) transcripts that were hybrid selected by pCRP5, a liver C-reactive protein (CRP)-specific cDNA (Woo, P., J.R. Korenberg, and A.S. Whitehead. 1985. J. Biol. Chem. 260:13384). Three hybrid-selected cDNA clones, HScDNA1, HScDNA3, and HScDNA8, were isolated and characterized. Nucleotide sequence analysis of the 5' end of the smaller clones, HScDNA1 and HScDNA8, demonstrated that these two PBMC clones are homologous to the 3' and 5' ends, respectively, of pCRP5. Our largest clone, HScDNA3, is larger than pCRP5, extending beyond both the 5' and 3' limits of pCRP5. Therefore, HScDNA3 was coded by human PBMC and not by the hybrid selection vehicle, pCRP5. HScDNA3 lacks the intervening sequence verifying that this clone is DNA made from a PBMC mRNA and not genomic DNA. The complete nucleotide sequence revealed that HScDNA3 is greater than 99% homologous to the CRP gene. These results demonstrate that PBMC express the CRP gene. Based on our previous report, which shows that peripheral blood cells synthesize a peptide recognized by anti-CRP (Kuta, A.E., and L.L. Baum. 1986. J. Exp. Med. 164:321), in conjunction with the data presented here, we conclude that human PBMC can synthesize CRP.

Materials and Methods

Isolation of PBMC. From each of four normal healthy human individuals, 100 ml of whole blood was collected into sodium heparin, pooled, and mixed with an equal volume of Sepacell-MN (Sepratech Corp., Oklahoma City, OK). PBMC were isolated and the cell count and viability were determined by trypan blue exclusion.

Cloning of HScDNA. Acid guanidinium thiocyanate-phenol-chloroform extraction (5) was used to isolate total RNA from PBMC. The plasmid pCRP5 constructed by Dr. Alexander Whitehead (Harvard Medical School, Boston, MA) (6), was a generous gift from Dr. Harvey Colton (Washington University, St. Louis, MO). The 1.6-kb PstI insert band from pCRP5 was immobilized on nitrocellulose and used in hybrid selection as previously described (7). CRP-specific RNA was isolated from 1.7 mg of PBMC total RNA. A cDNA synthesis kit (Pharmacia Fine Chemicals, Piscataway, NJ) was used to synthesize HScDNA from the hybrid-selected PBMC RNA. The HScDNA was ligated into the EcoRI cloning site of λZAPIII (Stratagene Cloning Systems, La Jolla, CA) and transfected into Escherichia coli strain XLI-Blue (Stratagene Cloning Systems).

Identification of HScDNA1, HScDNA3, and HScDNA8. An oligolabeling kit (Pharmacia Fine Chemicals) was used to radiolabel the purified 1.6-kb PstI insert band from pCRP5 with 32P-dCTP. A probe with specific activity of 1.9 × 107 cpmp/μg of fragment.
was obtained. Two nitrocellulose replicas were lifted from titer plates that contained 0.1, 1.0, or 10 µl of the HScDNA library. A DNA hybridization method (8) was used to screen the nitrocellulose lifts with the pCRP5 insert probe. 12 positive HScDNA clones identified from the autoradiogram of the HScDNA library screening were plaque purified, and their size was determined. The three largest clones, HScDNA1, HScDNA3, and HScDNA8, contain EcoRI inserts of 1.0, 1.6, and 0.8 kb, respectively, and were characterized further by sequence analysis.

Sequence Analysis of HScDNA1, HScDNA3, and HScDNA8.
Both strands of the cDNA insert fragment from HScDNA3 were subcloned into M13mp18 and M13mp19. Nested deletion subclones of both strands were constructed using the Cyclone I Biosystem (International Biotechnologies, Inc., New Haven, CT). The 5' limit of HScDNA8 was determined by subcloning the cDNA insert into MP13mp18 and sequencing. The 5' limit of HScDNA1 was determined by sequencing this recombinant λ ZAPII clone directly. Single-stranded DNA templates prepared from M13 subclones or directly from the recombinant λ ZAPII clone were sequenced by a dideoxy chain termination method using the Sequenase kit (United States Biochemical Corp., Cleveland, OH). A universal M13 primer (provided in the Sequenase kit) was used in the sequencing reactions of the M13 subclones. The T3 primer (Stratagene Cloning Systems) was used in the sequencing reactions of recombinant λ ZAPII clones.

Results and Discussion
Our earlier studies demonstrated that anti-CRP immunoprecipitates a surface peptide from IL-1- and IL-2-stimulated lymphocytes (2). This peptide is not acquired exogenously from CRP found in serum but is synthesized by the lymphocytes (2). Since the only known site of CRP synthesis is the hepatocyte, we set out to determine if the anti-CRP binding peptide produced by PBLs is CRP or an antigenically related peptide. The isolation and nucleotide sequence of pCRP5, a 1.6-kb CRP-specific cDNA synthesized from human liver mRNA, was previously reported (6). RNA was isolated from unstimulated human PBMC and was hybrid selected using pCRP5. It was then converted into cDNA and cloned into an EcoRI cloning site of λ ZAPII phage to construct HScDNA clones. When the HScDNA clones were screened with radiolabeled pCRP5, we found that the liver cDNA hybridized strongly to three PBMC clones, HScDNA1, HScDNA3, and HScDNA8, which contained cDNA inserts of 1.0, 1.6, and 0.8 kb, respectively.

A partial nucleotide sequence analysis was performed on the smaller clones, HScDNA8 and HScDNA1, to determine whether these clones represent the known CRP transcript or a CRP-related transcript. We sequenced 304 nucleotides from the 5' end of HScDNA8 and 115 nucleotides from the 5' end of HScDNA1. When these sequences were compared to pCRP5, we found that the 0.8-kb insert of HScDNA8 is homologous to the 5' end of pCRP5, while the 1.0-kb insert of HScDNA1 is homologous to the 3' end of pCRP5 (Fig. 1). The CRP gene contains a 278-bp intervening sequence that is defined by nucleotides 330–607 (6). The absence of nucleotides 330–607 from HScDNA8 (Fig. 1) demonstrates that the insert contained in HScDNA8 represents a PBMC transcript and not PBMC genomic DNA, which may have contaminated our hybrid selection and cloning procedures. With one exception the nucleotides sequenced from HScDNA1 and HScDNA8 display 100% homology to pCRP5. The exception is a substitution located at position 1056. HScDNA1 contains a G at this position while pCRP5 contains an A (Fig. 2).

Although our results indicate that HScDNA1 and HScDNA8 represent CRP transcripts, they do not eliminate the possibility that our HScDNA clones were derived from fragments of pCRP5 that may have been eluted from the nitrocellulose during the hybrid selection step, rather than from PBMC transcripts. Since the entire CRP transcript is not represented by pCRP5, the ends of our largest clone, HScDNA3, were sequenced to determine if they contained any portions of the CRP transcript that are not present in pCRP5. Our data show that the 5' limit of HScDNA3 extends five nucleotides beyond the 5' limit of pCRP5 (Fig. 1). Also, HScDNA3 contains an additional 23 nucleotides on the 3' end that are not present in pCRP5 (Fig. 1). These additional nucleotides observed in HScDNA3 are homologous to the corresponding nucleotides of the CRP gene (Fig. 2) and confirm that HScDNA3 is not derived from pCRP5. Furthermore, since HScDNA3 lacks the intervening sequence it is not derived from genomic DNA, but rather from a PBMC transcript.

The human genome contains a single copy CRP gene and a pseudogene; these display 50–80% region specific identity (9). Since the complete nucleotide sequence of HScDNA3 is >99% homologous to the CRP gene with all but 20 of the 1,645 nucleotides of HScDNA3 being identical to the sequence of the CRP gene (99% identity), we conclude that these HScDNA clones are not transcripts of the pseudogene (Fig. 2). The reduced homology in the last 15 nucleotides of HScDNA3 may reflect the limitation of the polymerase used for cDNA synthesis or genetic polymorphism. Alter-
natively, HScDNA3 might have been damaged as a result of a fragmentation that may have occurred in this region during cloning. The cDNA synthesis was initiated from a poly(T) primer annealed to PBMC RNA. No poly(A) tail is observed in HScDNA3, suggesting that this cDNA did fragment. Nevertheless, the extensive nucleotide homology between HScDNA3 and the coding region of the CRP gene verifies that PBMC transcribe the CRP gene.

While hepatocytes express secreted CRP, we provided evidence in a previous report that shows that CRP expressed by peripheral blood cells is a membrane protein that does not appear to be secreted (2, 3). Therefore, we examined the deduced amino acid sequence of HScDNA3 to determine if it has an alternate or additional transmembrane region that pCRP5 does not have or any other differences that may account for the expression of a membrane peptide by peripheral blood cells and a secreted peptide by liver cells from the same CRP gene. The only difference found near the 3' end of the translated region is located at position 1056 (Fig. 2). HScDNA3, as well as HScDNA1, have a G substituted for the A observed at this position in pCRP5. However, this is a neutral substitution that does not change the amino acid coded for by the affected codon. It is, therefore, unlikely that this nucleotide difference allows the expression of membrane CRP by lymphocytes. Other sequence differences were observed in the 3' untranslated region of HScDNA3 as compared with pCRP5. These include the addition of a single C after nucleotide 1364, the addition of two Gs after nucleotide 1654, and the substitution of a C for an A at position 1684 (Fig. 2). Since nucleotides 1364, 1654, and 1684 are located in the 3' untranslated region of the CRP transcript, these differences are unlikely to account for the expression of variant forms of the CRP peptide by different cell types. Therefore, the nucleotide sequence of HScDNA3 suggests that the CRP peptide expressed by peripheral blood cells has a primary structure identical to the pre-CRP peptide expressed by liver cells. Although PBMC do not appear to add a transmembrane region or alter the COOH terminus of the CRP transcript, other mechanisms, such as usage of a phosphatidylinositol glycan anchor, could account for its presence as a membrane protein. Clearly, variations in the processing and assembly of CRP subunits, variations in other membrane proteins, or variations in the signals received by cells could also account for the expression of a membrane protein by peripheral blood cells and a secreted protein by liver cells from a single CRP gene.

While it is unlikely that the few nucleotide differences observed between our HScDNA clones and pCRP5 or the CRP gene play a role in modifying the form of the CRP peptide expressed in PBMC, they may represent genetic variations within the CRP gene. This is supported by the finding that when we compared the nucleotide sequence of our HScDNA clones with the CRP gene sequence reported by Goldman and coworkers (9, 10), rather than to the sequence of pCRP5 and the CRP gene reported by Woo et al. (6), we found that our sequence is identical to the CRP gene at positions 1056 and 1684. There appear to be several genetic variations within the CRP gene as demonstrated by sequence discrepancies reported by various investigators at positions 1056, 1444, and 1684 of the CRP gene and CRP-specific cDNA clones. Goldman et al. (9) previously suggested this when he reported variations in the length of the polyGT stretch located within the intervening sequence of the CRP gene.

Although PBLs and liver cells may synthesize identical pre-CRP peptides, the CRP molecule expressed by peripheral blood cells may differ in tertiary structure from the mature CRP molecule secreted by the liver. Immunofluorescent studies showed that a CRP epitope that is present on unprocessed CRP and not on serum CRP is preferentially expressed on lymphocytes (11). Perhaps the pre-CRP peptide synthesized by PBMC is incompletely processed or reacts with cellular factors that result in the expression of a conform-
tionally altered molecule that contains a region that is cryptic in the pentameric form of CRP found in the serum. The newly exposed region may function as a membrane anchor, associate with a phosphatidylinositol glycan anchor, or associate with some other protein present in the membrane.

Many of the activities attributed to CRP involve the immune response. It seems logical that hepatocytes might synthesize and release pentameric CRP, which is protected from denaturation and remains inactive until it reaches the site of inflammation, while lymphocytes at the site of inflammation or malignancy might synthesize and express the conformationally active form. Along with demonstrating PBMC expression of CRP, these data support studies describing a role for cell surface CRP in cell-mediated immunity.

The authors would like to thank Donna Szydlowski for helping to prepare this manuscript.

This work was supported in part by grant RR-05366 from the National Institutes of Health, Bethesda, MD.

Address correspondence to Kenneth D. Beaman, Department of Microbiology and Immunology, The Chicago Medical School, 3333 Green Bay Road, North Chicago, IL 60064.

Received for publication 31 October 1990.

References

1. Kushner, I., and G. Feldmann. 1978. Control of the acute phase response. Demonstration of C-reactive protein synthesis and secretion by hepatocytes during acute inflammation in the rabbit. J. Exp. Med. 148:466.
2. Kuta, A.E., and L.L. Baum. 1986. C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes. J. Exp. Med. 164:321.
3. Baum, L.L., K.K. James, R.R. Glaviano, and H. Gewurz. 1983. Possible role for C-reactive protein in the human natural killer cell response. J. Exp. Med. 157:301.
4. Ikuta, T., H. Okubo, H. Ishibashi, Y. Okumura, and K. Hayashida. 1986. Human lymphocytes synthesize C-reactive protein. Inflammation. 10:223.
5. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156.
6. Woo, P., J.R. Korenberg, and A.S. Whitehead. 1985. Characterization of genomic and complementary DNA sequence of human C-reactive protein, and comparison with the complementary DNA sequence of serum amyloid P component. J. Biol. Chem. 260:13384.
7. Jagus, R. 1987. Hybrid selection of mRNA and hybrid arrest of translation. In Guide to Molecular Cloning Techniques. S.L. Berger and A. R. Kimmel, editors. Academic Press, Inc., San Diego.
8. Ausubel, F.M., R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith, and K. Struhl. 1987. Current Protocols in Molecular Biology. IV Analysis of DNA Sequences by blotting and Hybridization. Green Publishing Assoc. and Wiley-Interscience, New York. 2.9.1–2.9.12.
9. Goldman, N.D., T. Liu, and K. Lei. 1987. Structural analysis of the locus containing the human C-reactive protein gene and its related pseudogene. J. Biol. Chem. 262:7001.
10. Lei, K., T. Liu, G. Zon, E. Soravia, T. Liu, and N.D. Goldman. 1985. Genomic DNA sequence for human C-reactive protein. J. Biol. Chem. 260:13377.
11. Samberg, N.L., R.A. Bray, H. Gewurz, A.L. Landay, and L.A. Potempa. 1988. Preferential expression of neo-CRP epitopes in the surface of human peripheral blood lymphocytes. Cell. Immunol. 116:86.